(AOF) – Guerbet announces turnover as of September 30, 2023 at 573.9 million euros, up 0.8% compared to the same period in 2022. At constant exchange rate (CER) the growth of turnover over 9 months stands at 2.7%. Sales in the 3rd quarter of 2023 stood at 195.2 million euros, up 2.3% at CER. This development “confirms Guerbet’s financial objectives for the entire current financial year and the next”, affirms the specialist in contrast products and solutions for medical imaging.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.